Table 1 Demographic and clinical characteristics of the study patients with genotype-4 chronic hepatitis C

Age (years, mean ± SD & range)

43.2 ± 12.9 (21–62)

Sex (male/female)

119/36 (76.8/23.2%)

BMI (kg/m², mean ± SD)

25.6 ± 2.9

Average weight (BMI < 25)

68 (43.9%)

Overweight (BMI 25–30)

87 (56.1%)

Obese (BMI > 30)

0

Serum albumin (g/dL, mean ± SD)

3.8 ± 0.7

Serum bilirubin (mg/dL, median & range)

1.4 (0.6–5.8)

ALT (U/L, mean ± SD)

41.5 ± 20.3

AST (U/L, mean ± SD)

38.9 ± 18.3

ALP (U/L, mean ± SD)

119.4 ± 48.7

Platelet count (10³/µL, U/L, mean ± SD)

201.7 ± 72.2

HCV RNA (IU/mL, median & range)

4.5 × 10⁵ (9 × 10³–8 × 10⁶)

Histopathological data

Fibrosis stage (F1/F2/F3/F4)

54/62/13/26 (34.8/40/8.4/16.8)

Hepatitis grades (G1/G2/G3)

68/58/29 (43.9/37.4/18.7)

Steatosis (no/mild/moderate/severe)

23/44/44/21 (29.7/28.4/28.4/13.5)

MDCT data

CT ratio (mean ± SD, range)

1.1 ± 0.2 (0.3–1.4)

MRI data

T1-fat fraction (median & range)

− 13.5 (− 32.5 to 30.4)

Fat percentage (median & range)

4.8 (− 5.2 to 33.4)

T2 fat suppression (median & range)

0.1 (− 22.5 to 22.2)

Proton density fat fraction% (PDFF) (median & range)

6.2 (0.6–35.2)

ADC for hepatic fibrosis (× 10⁻³ mm²/s) (median & range)

1.2 (0.97–1.4)